Publicaciones en colaboración con investigadores/as de Maastricht University Medical Centre (8)

2024

  1. Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial

    Hypertension Research

  2. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

    Heart, Vol. 110, Núm. 19, pp. 1180-1187

2023

  1. Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study

    Circulation: Heart Failure, Vol. 16, Núm. 5, pp. E009694

2022

  1. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

  2. Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial

    ESC Heart Failure, Vol. 9, Núm. 6, pp. 4352-4357

  3. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial

    European Journal of Heart Failure, Vol. 24, Núm. 5, pp. 771-778

2021

  1. The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy – A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy

    European Journal of Heart Failure, Vol. 23, Núm. 6, pp. 933-944

  2. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: The heart 'OMics' in AGEing (HOMAGE) randomized clinical trial

    European Heart Journal, Vol. 42, Núm. 6, pp. 684-696